Sickle-cell disease is a general term for a group of genetic disorders caused by sickle hemoglobin (Hgb S or Hb S). In many forms of the disease, the red blood cells change shape upon deoxygenation because of polymerization of the abnormal sickle hemoglobin. This process damages the red blood cell membrane, and can cause the cells to become stuck in blood vessels. This deprives the downstream tissues of oxygen and causes ischemia and infarction. The disease is chronic and lifelong. Individuals are most often well, but their lives are punctuated by periodic painful attacks. In addition to periodic pain, there may be damage of internal organs, such as stroke. Lifespan is often shortened with sufferers living to an average of 40 years. It is common in people from parts of the world where malaria is or was common, especially in sub-saharan Africa or in descendents of those peoples. Sickle-cell disease can occur in any individual of any color or ethnicity, however.

Types and terminology

---

"Sickle-cell anemia" is the name of a specific form of sickle-cell disease in which there is homozygosity for the mutation that causes Hgb S. Other forms of sickle-cell disease include:

• sickle-hemoglobin C disease
• sickle beta-plus-thalassemia
• sickle beta-zero-thalassemia

Unlike sickle-cell anemia, these other forms of sickle-cell disease are compound heterozygous states in which the person has only one copy of the mutation that causes Hgb S and one copy of another abnormal hemoglobin gene. It is important to know that "sickle-cell anemia" is the proper name of a specific type of "sickle-cell disease", and that "sickle-cell disease" is a non-specific term. Because the different forms of sickle-cell disease are quite different, one must be sure to specify the exact form of the disease in question.

More on [ Sickle-cell disease ]

The Pediatric Infectious Disease Journal - Current Table Of Contents

Live Attenuated Human Rotavirus Vaccine, RIX4414, Provides Clinical Protection in Infants Against Rotavirus Strains With and Without Shared G and P Genotypes: Integrated Analysis of Randomized Controlled Trials.
Page: 261DOI: 10.1097/INF.0b013e3181907177Authors: De Vos, Beatrice MD *; Han, Htay Htay MD *; Bouckenooghe, Alain MD *; Debrus, Serge PhD *; Gillard, Paul MD *; Ward, Richard PhD +; Cheuvart, Brigitte PhD *
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Motavizumab, a Humanized, Enhanced-Potency Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus Infection in At-Risk Children.
Page: 267DOI: 10.1097/INF.0b013e31818ffd03Authors: Abarca, Katia MD *; Jung, Elizabeth MD +; Fernandez, Pilar MD ++; Zhao, Liang PhD [S]; Harris, Brian MS [S]; Connor, Edward M. MD [S]; Losonsky, Genevieve A. MD [S]; for the Motavizumab Study Group

Subscribe to Conditions_and_Diseases RSS feed